KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBT Margin (2017 - 2025)

Historic EBT Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 120.61%.

  • Aquestive Therapeutics' EBT Margin fell 356200.0% to 120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.42%, marking a year-over-year increase of 5840000.0%. This contributed to the annual value of 4380.06% for FY2024, which is 43649900.0% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBT Margin is 120.61%, which was down 356200.0% from 135.44% recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' EBT Margin peaked at 72.46% during Q1 2023, and registered a low of 618.35% during Q2 2021.
  • Its 5-year average for EBT Margin is 128.5%, with a median of 109.36% in 2022.
  • Per our database at Business Quant, Aquestive Therapeutics' EBT Margin surged by 4145800bps in 2022 and then crashed by -1788900bps in 2024.
  • Aquestive Therapeutics' EBT Margin (Quarter) stood at 261.28% in 2021, then surged by 56bps to 115.63% in 2022, then surged by 48bps to 60.65% in 2023, then skyrocketed by 163bps to 38.2% in 2024, then crashed by -416bps to 120.61% in 2025.
  • Its EBT Margin stands at 120.61% for Q3 2025, versus 135.44% for Q2 2025 and 262.96% for Q1 2025.